Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KATERZIA vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KATERZIA (bosentan) is an endothelin receptor antagonist (ERA) that blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. This inhibits ET-1-mediated vasoconstriction and smooth muscle proliferation, reducing pulmonary vascular resistance and pulmonary arterial pressure.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and decrease clinical worsening in patients with WHO class II–IV symptoms,Off-label: Treatment of digital ulcers in systemic sclerosis; prevention of recurrence of digital ulcers; management of inoperable chronic thromboembolic pulmonary hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
5 mg orally once daily for 21 days, then 7 days off, repeated in 28-day cycles.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life is approximately 9-12 hours in healthy adults. In patients with hypertension or hepatic impairment, half-life may be prolonged up to 15-20 hours, necessitating dose adjustment.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Primarily metabolized by CYP2C9 and CYP3A4 to three major metabolites (Ro 48-5033, Ro 47-8634, Ro 64-1056). Induces CYP2C9 and CYP3A4; also induces CYP2C19.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal elimination accounts for approximately 60-80% of the administered dose, predominantly as unchanged drug via glomerular filtration and active tubular secretion. Biliary/fecal excretion is minimal, <5%.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Approximately 95-98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. High binding limits tissue distribution and affects free drug concentration.
92-98% bound to plasma proteins (primarily albumin)
Volume of distribution is approximately 0.7-1.2 L/kg (range 50-80 L for a 70 kg adult), indicating moderate tissue distribution beyond plasma volume.
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral bioavailability is approximately 30-40% due to extensive first-pass hepatic metabolism. Food may reduce bioavailability by 20-30%, so dosing should be consistent with respect to meals.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 5 mg orally once daily for 21 days, then 7 days off. Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients.
Not recommended for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment required; monitor for adverse events due to potential age-related renal and hepatic decline.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
WARNING: HEPATOTOXICITY. Bosentan can cause serious hepatic injury, including acute liver failure, requiring baseline and monthly monitoring of liver enzymes. Discontinue if ALT/AST >3x ULN accompanied by symptoms or bilirubin >2x ULN.
No FDA black box warning.
Hepatotoxicity (monitor LFTs monthly), hepatorenal syndrome; peripheral edema; fluid retention; may cause hypotension; pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema; decreases hemoglobin and hematocrit (monitor at 1 and 3 months, then every 3 months); decreases sperm count; reduces efficacy of hormonal contraceptives (use alternative contraception); caution in hepatic impairment (Child-Pugh Class A; contraindicated in moderate to severe impairment); caution in elderly; not recommended in patients with severe anemia.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Absolute: Hypersensitivity to bosentan or any component; moderate to severe hepatic impairment (Child-Pugh Class B or C); baseline AST/ALT >3× ULN; concomitant use with cyclosporine A (increases bosentan levels and hepatotoxicity); concomitant use with glyburide (increases risk of liver enzyme elevations); pregnancy (teratogenic in animals – can cause birth defects; must exclude pregnancy before initiation and monthly thereafter).
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Take with food to improve tolerability and reduce gastrointestinal adverse effects. Avoid grapefruit juice as it may increase treprostinil exposure. Avoid alcohol as it may exacerbate vasodilation and hypotension.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
Pregnancy Category C. First trimester: animal studies show fetal toxicity; no adequate human data. Second/third trimester: may cause fetal renal impairment, oligohydramnios, and skull ossification defects due to direct renin-angiotensin system inhibition.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
No human data; M/P ratio unknown. Excreted in rat milk. Due to potential risk of hypotension and renal impairment in nursing infants, discontinue drug or breastfeeding, considering importance to mother.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
No specific dose adjustments established for pregnancy. However, due to increased plasma volume, efficacy may be reduced; monitor therapeutic response. Contraindicated in pregnancy; avoid use.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
KATERZIA (oral treprostinil) is a prostacyclin analogue used for pulmonary arterial hypertension (PAH). Monitor for prostacyclin-related side effects (headache, nausea, diarrhea, jaw pain, flushing). Dose titration is critical; increase by 0.25 mg BID or 0.125 mg TID every 3-4 days as tolerated. Avoid abrupt discontinuation due to risk of rebound pulmonary hypertension. Use with caution in patients with hepatic impairment; reduce starting dose in moderate impairment.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take KATERZIA exactly as prescribed, with food to reduce gastrointestinal side effects.,Do not stop taking this medication suddenly; consult your doctor before making any changes.,Common side effects include headache, nausea, diarrhea, jaw pain, and flushing; report severe or persistent symptoms.,Avoid alcohol and grapefruit juice as they may interact with the medication.,Store tablets in the original container at room temperature, away from moisture and light.,If you miss a dose, skip it and take the next dose at the scheduled time; do not double dose.,Inform your healthcare provider of all medications you are taking, especially antihypertensives, anticoagulants, and NSAIDs.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KATERZIA vs AFEDITAB CR, answered by our medical review team.
KATERZIA is a Calcium Channel Blocker that works by KATERZIA (bosentan) is an endothelin receptor antagonist (ERA) that blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. This inhibits ET-1-mediated vasoconstriction and smooth muscle proliferation, reducing pulmonary vascular resistance and pulmonary arterial pressure.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KATERZIA and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KATERZIA is: 5 mg orally once daily for 21 days, then 7 days off, repeated in 28-day cycles.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KATERZIA and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KATERZIA is classified as Category C. Pregnancy Category C. First trimester: animal studies show fetal toxicity; no adequate human data. Second/third trimester: may cause fetal renal impairment, oligohydramnios, and sk. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.